

Baseline Characteristics	Development cohort, n=6766		Validation cohort, n=8300	
	n _a ¹	Median (IQR) or No. (%)	n _a ¹	Median (IQR) or No. (%)
DEMOGRAPHICS				
Gender – Female	6766	2148 (31.8)	8300	2947 (35.5)
Age (years)	6766	66 (61-71)	8300	65 (59-70)
Race – Caucasian	6766	4602 (68.0)	8300	4779 (57.6)
Asian	6766	1158 (17.1)	8300	925 (11.1)
Other	6766	1006 (14.9) ²	8300	2595 (31.3)
PHYSICAL EXAMINATION				
BMI (kg/m ²)	6734	28.6 (25.7-32)	8215	29.6 (26.5-33.2)
Weight (kg)	6763	81 (70-92)	8272	82 (72-94.2)
Waist circumference (cm)	6753	99 (90-108)	8233	101 (92-110)
Duration of diabetes mellitus (years)	6707	8 (3-16)	7683	5.5 (3.5-9.5)
LABORATORY DATA				
Systolic blood pressure (mmHg)	6762	144 (131-155)	8285	140.5 (129.5-154.5)
Diastolic blood pressure (mmHg)	6762	82 (75-89)	8276	81 (74-89)
Mean arterial blood pressure (mmHg)	6762	102.7 (95-110)	8274	101.33 (93.3-110)
eGFR MDRD (ml/min per 1.73m ²)	6751	72.5 (59.5-87.1)	8300	76.2 (63.8-90.3)
eGFR CKD-EPI (ml/min per 1.73m ²)	6751	71.6 (58.1-86.1)	8300	75.8 (62.5-90)
Serum creatinine (mg/dL)	6751	1.0 (0.9-1.2)	8300	1.0 (0.8-1.1)
Glucose (mg/dL)	6736	141.2 (116.2-177.9)	8062	105.3 (87.7-128.1)
UACR (mg/g)	6766	57.6 (25.0-214.4)	8300	41.2 (18.5-144.0)
Albuminuria status - Normo	6766	5246 (77.5)	8300	6886 (83)
Fasting LDL (mg/dL)	6505	106.0 (85.1-131.5)	8181	104.4 (80.4-131.5)
CLINICAL HISTORY				
Myocardial infarction	6766	2622 (38.8)	8300	2888 (34.8)
Coronary artery disease	6766	4291 (63.4)	8299	381 (4.6)
Peripheral artery disease	6766	966 (14.3)	8300	235 (2.8)
Hypertension	6766	5297 (78.3)	8299	6813 (82.1)
CABG	6766	1317 (19.5)	8300	1046 (12.6)
PTCA	6766	1547 (22.9)	8299	1778 (21.4)
COMORBIDITIES				
MACE ³	6766	4340 (64.1)	8300	4987 (60.1)
Stroke/TIA	6766	1225 (18.1)	8300	1142 (13.8)
Peripheral artery disease	6766	1014 (15)	8300	77 (1)
Laser therapy for diabetic retinopathy	6766	619 (9.2)	8300	170 (2.1)
MEDICATIONS				
Number of antihypertensive drugs - 0	6766	0 (0)	8298	736 (8.9)
1	6766	1402 (20.7)	8298	2021 (24.4)
2	6766	2744 (40.6)	8298	2905 (35)
3	6766	1969 (29.1)	8298	1914 (23.1)
4	6766	594 (8.8)	8298	659 (8)
5	6766	57 (0.8)	8298	63 (0.8)
Previous ACEI/ARBs	6766	4846 (71.6)	8300	4688 (56.5)
Statin	6766	3737 (55.2)	8300	4422 (53.3)
Beta-blocker	6766	3480 (51.4)	8298	4239 (51.1)
Any antiplatelet drug	6766	5066 (74.9)	8300	806 (9.7)
Diuretic	6766	2368 (35)	8299	3103 (37.4)
Calcium-channel blocker	6766	2473 (36.6)	8300	2025 (24.4)

¹ n_a number of participants with available data.

² The category 'Other' was divided into 87 Arab/Persian, 208 Black or colored African, 634 native Latin and 77 other.

³ MACE, i.e. major atherosclerotic cardiac events, is defined as myocardial infarction, stable or unstable angina, CABG surgery, or PTCA/atherectomy/PCI.

Abbreviations: ACEI/ARBs, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; eGFR CKD-EPI, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation; IQR, interquartile range; LDL, Low-Density Lipoprotein; MACE, major atherosclerotic cardiac events; PTCA, percutaneous transluminal coronary angioplasty; TIA, transient ischemic attack; UACR, urinary albumin-creatinine ratio.

Conversion factors: To convert creatinine to mmol/L, multiply by 88.4; glucose to mmol/L, multiply by 1/18.15; LDL to mmol/L multiply by 1/38.67; UACR to mg/mmol/L multiply by 0.1133.